Alector Inc
F:0Z2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Alector Inc
F:0Z2
|
US |
|
T
|
Transurban Group
F:TU9
|
AU |
|
D
|
Deere & Co
SWB:DCO
|
US |
|
Shiseido Co Ltd
OTC:SSDOF
|
JP |
|
T
|
Tsingtao Brewery Co Ltd
HKEX:168
|
CN |
|
MKS Instruments Inc
NASDAQ:MKSI
|
US |
|
T
|
TUI AG
LSE:TUI
|
DE |
|
B
|
Basf Se
XHAM:BAS
|
DE |
|
J
|
J.Front Retailing Co Ltd
OTC:JFROF
|
JP |
Alector Inc
Alector Inc. is a clinical-stage biotechnology company working on medicines for brain diseases such as Alzheimer’s and frontotemporal dementia. Its idea is to use the body’s immune system, especially cells in the brain called microglia, to help clear harmful proteins and slow disease progression. The company does not sell approved drugs itself; it develops drug candidates and tests them in clinical trials. Alector’s main customers are not patients today but large pharmaceutical partners and, eventually, healthcare systems if its drugs win approval. It makes money mainly through collaboration and license deals with drugmakers, which can include upfront payments, research funding, milestone payments, and future royalties if a partnered drug reaches the market. That means its business depends on advancing a small number of experimental programs rather than selling a broad line of products. What makes Alector different is its focus on immunology inside the brain, which is a less common path in neurodegeneration research. It sits upstream in the drug supply chain as a discovery and development company: it invents candidates, partners when useful, and tries to turn academic biology into medicines. For investors, the key point is that Alector is a research-driven biotech, so its value depends heavily on scientific results, trial progress, and partner support rather than steady product sales.
Alector Inc. is a clinical-stage biotechnology company working on medicines for brain diseases such as Alzheimer’s and frontotemporal dementia. Its idea is to use the body’s immune system, especially cells in the brain called microglia, to help clear harmful proteins and slow disease progression. The company does not sell approved drugs itself; it develops drug candidates and tests them in clinical trials.
Alector’s main customers are not patients today but large pharmaceutical partners and, eventually, healthcare systems if its drugs win approval. It makes money mainly through collaboration and license deals with drugmakers, which can include upfront payments, research funding, milestone payments, and future royalties if a partnered drug reaches the market. That means its business depends on advancing a small number of experimental programs rather than selling a broad line of products.
What makes Alector different is its focus on immunology inside the brain, which is a less common path in neurodegeneration research. It sits upstream in the drug supply chain as a discovery and development company: it invents candidates, partners when useful, and tries to turn academic biology into medicines. For investors, the key point is that Alector is a research-driven biotech, so its value depends heavily on scientific results, trial progress, and partner support rather than steady product sales.
Key Catalyst Approaching: Alector expects pivotal Phase III INFRONT-3 trial data for latozinemab in FTD-GRN by mid-fourth quarter 2025.
Regulatory Engagement: INFRONT-3 statistical plan was amended to include plasma progranulin as a co-primary endpoint following a specific FDA request, reinforcing the importance of this biomarker.
Strong Clinical Rationale: Latozinemab has shown robust, consistent elevation of progranulin in prior studies and is well tolerated, with no major safety signals reported.
Financial Position: Ended Q2 with $307.3 million in cash, providing expected runway into the second half of 2027.
Updated Guidance: 2025 collaboration revenue guidance is now $13–18 million; R&D spend projected at $130–140 million; G&A expenses at $55–65 million.
Pipeline Progress: AL101 Phase II in early Alzheimer’s completed enrollment (trial completion expected in 2026); multiple preclinical programs using Alector’s brain delivery platform are advancing.
Unmet Need Highlighted: FTD-GRN remains a devastating disease with no approved therapies; a meaningful slowing of decline (even 25%) would be considered clinically significant in this population.
